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Abstract Metastatic lesions of the pancreas are uncom-
mon, accounting for approximately 2% of pancreatic
malignancies. Many tumours involve the pancreas sec-
ondarily and may manifest with different clinical and
imaging characteristics. Although many patients have
widespread disease, isolated metastases can be found.
Surgical management is associated with improved sur-
vival in these cases. The experience of the pancreatic
surgery unit and imaging department of our hospital in
many patients presenting with pancreatic metastases is
presented, and a review of the recent literature is
undertaken.
Main Messages
￿ The early recognition of secondary pancreatic tumours on
US, CT and MRI is extremely important.
￿ Pancreatic metastases may mimic primary pancreatic
adenocarcinoma or induce acute pancreatitis.
￿ Most pancreatic metastases are discovered on a CT
examination performed for follow-up.
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Introduction
Unlike primary pancreatic carcinoma, metastatic lesions of
the pancreas are uncommon and account for approximately
2% of pancreatic malignancies. At autopsy the pancreas has
been found to be a site of metastases in a wide range (3–
12%) of patients with malignant tumours [1].
A variety of extrapancreatic tumours can involve the pan-
creas secondarily and may manifest with different clinical and
imaging characteristics. The most common primary tumours
to give rise to pancreatic metastases are lung cancer, breast
cancer, renal cell carcinoma, malignant melanoma, carcinoma
of gastrointestinal origin and prostate cancer. Less commonly
metastases from osteosarcoma, leiomyosarcoma, chondrosar-
coma, and Merkel cell carcinoma, have been reported [2].
Although many patients have widespread disease, isolated
metastases can be found. Surgical management seems to be
associated with improved survival in these cases [3–5]. More-
over resection is most likely to be warranted in patients present-
ing after a long disease-free interval following primary cancer
treatment, suggesting a biological pattern of slow growth.
The early recognition of secondary pancreatic tumours on
ultrasonography (US), computed tomography (CT), and
magnetic resonance imaging (MRI) is extremely important,
so that the patient will benefit from the appropriate treatment
according to disease prognosis.
Primary tumours and frequency of pancreatic
metastases
Almost any tumour type may metastasize to the pancreas,
but in an analysis of a surgical and autopsy database, the
majority of tumours found in the surgical database were
lymphomas and carcinomas of the stomach, kidney, and
lung, whereas in the autopsy database, metastasis was most
commonly from the lung, followed by the GI tract and
kidney [6].
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found renal cell carcinoma to be the most frequent primary
histopathology (62%), followed by non-small-cell lung can-
cer, and melanoma [7]. In this series, postoperative morbid-
ity was 25%, mortality was 6%, and the overall actuarial
survival rate for 2 and 5 years was 62 and 25%, which
indicates that resection of metastatic disease to the pancreas
is safe and may offer some survival benefit in selected patients.
Other primary malignancies that have been reported to
give rise to pancreatic metastases are thyroid, prostate, ovar-
ian, hepatocellular carcinomas, and various types of sarcomas
[6, 8, 9].
The interval from diagnosis of an extrapancreatic primary
tumour to subsequent detection of a pancreatic metastasis
varies but is usually between 1 and 3 years [9]. Metastases
from renal cell carcinoma may present many years after
resection of the primary tumour. McNichols et al [10]
reported that 11% of patients developed metastases 10 or
more years after nephrectomy, even with early stage disease.
The longest interval was reported by Muranaka [11], who
observed pancreatic metastases 27 years after treatment of
the primary renal tumour. Rarely, a pancreatic metastasis
may be discovered before the distant primary source is
known [9].
Clinical symptoms
Pancreatic metastases may directly invade the pancreatic
ductal epithelium and thus clinically mimic primary pancreat-
ic adenocarcinoma, or less commonly, induce acute pancrea-
titis. As a result, clinical symptoms produced by secondary
pancreatic tumours are variable and nonspecific, including
abdominal pain, back pain, weight loss, nausea, melaena,
jaundice, gastrointestinal obstruction, upper gastrointestinal
bleeding, and diabetic ketoacidosis [8, 9].
Pancreatic metastatic tumour may also be completely
asymptomatic. In a series of 18 patients with metastases to
the pancreas, 15 patients were asymptomatic and the pan-
creatic mass was detected on routine follow-up examination
[8]. Clinical signs of acute pancreatitis are rare, although
elevated serum amylase levels are often found [11].
Lesion distribution and morphology
Three patterns of metastatic involvement of the pancreas
have been described thus far. The first one, reported in 5–
10% of patients, is represented by many small nodules,
which can coalesce occasionally into larger masses [11,
12]. The attenuation of the neoplastic nodules may be var-
iable and generally depends on the histological type of the
causative primary tumour [12].
The second pattern, reported in 15–44% of patients, is
given by a diffuse infiltration of the pancreas, which leads to
a diffusely enlarged organ, with homogeneous density [11,
12]. However, the diffuse multiple form of metastatic pan-
creatic involvement may also show central areas of low
attenuation [9].
The last pattern, reported in 50–75% of cases, is given by
a solitary mass with an occasional hypodense focus on
contrast-enhanced CT, due to tumour necrosis (Figs. 1, 2, 3)
[11,12].However,thehypodensitymaynotbeapparentwhen
the metastasis is small, but may only appear as the tumour
becomes larger [9].
The location within the pancreas may be responsible for
some of the physical signs and symptoms. If located in the
head, the mass may easily cause obstruction of the bile duct
with subsequent jaundice or obstruction of the pancreatic
duct, which may in turn cause atrophy of the body and tail
and a beaded appearance of the dilated Wirsung’s duct [13].
In this group of patients the highest incidence of eleva-
tion of serum amylase is found, probably because of the
acinar destruction caused by the obstructed flow in the
Wirsung’s duct.
Fig. 1 A solitary pancreatic metastasis is seen on this contrast-
enhanced CT image (a), as a hypodense lesion with peripheral contrast
enhancement (arrow) in a 70-year-old man presenting with rectal
bleeding. The primary neoplasm in the sigmoid colon is also evident
(b)
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cation of localised and multifocal forms (Fig. 4), as well as
diffuse enlargement (Figs. 5, 6) without consideration of
density characteristics. This classification was adopted by
Kelekis et al [14] who first described the MR appearance of
pancreatic metastases.
Imaging methods and findings
The diagnosis of a metastasis to the pancreas begins with
suspicion based on the history of a relevant cancer. Most
pancreatic metastases are firstly discovered on a CT exam-
ination performed for follow-up of patients with history of
primary malignancy. However, all imaging studies such as
dynamic contrast-enhanced CT scans, magnetic resonance
imaging (MRI), endoscopic ultrasound (EUS) and contrast-
enhanced US may support that suspicion, especially if mul-
tiple tumours are noted [15].
On US examination, metastases appear as solid hypoe-
chogenic masses located within the pancreatic parenchyma
[16]. Cysts are generally not a feature. EUS may discover
small pancreatic metastases after negative CT scans [17].
Pancreatic metastases are more likely to have well-defined
margins compared to primary ductal adenocarcinoma that
usually presents with irregular margins, while there is no
statistically significant difference concerning tumour size,
echogenicity, and location [17].
EUS-guided FNA is safe and accurate for the diagnosis
of pancreatic metastases from different primary carcinomas.
However, effective sampling requires techniques that differ
from those used for other solid pancreatic masses. Use of
immunocytochemistry, when available, may help to confirm
a suspected diagnosis (Figs. 7, 8)[ 18].
The introduction of contrast-enhanced ultrasonography
(CEUS) has lead to great developments in the diagnostic
capabilities of ultrasound. The study of the pancreas is a
newand promising application ofCEUS. CEUSoffersadvan-
tages over conventional US for identifying pancreatic lesions
or for characterising pancreatic lesions already visible at US
[19].Theresultsofthistechniquearebetterinmetastasesfrom
hypervascular tumours such as renal cell cancer, neuroendo-
crine tumours, or hepatocellular carcinoma.
Circumscribed lesions (single or multifocal) appear iso-
dense or, more often, slightly hypodense on unenhanced CT
[1, 20]. Bulging of the gland contour is occasionally seen.
Fig. 2 A 65-year-old man suffering from lung cancer that caused
atelectasis of the left lower lobe (a). Left adrenal metastasis (arrow),
as well as hypodense metastastic infiltration of the pancreatic head
(arrowhead) are also seen (b). Note that both the vessels and the
pancreatic duct appear normal
Fig. 3 A gastric cancer (arrow) with nodal dissemination (arrowheads)
isvisible onthis contrast-enhancedCTimage(a) ina 63-year-old woman
presenting with anemia. A liver metastasis (arrow) as well as a small
hypodense heterogenous pancreatic head lesion (arrowhead) is also
demonstrated (b)
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of enhancement is usually demonstrated and a central area
of low attenuation may be clearly visible (Fig. 1). Rim
enhancement is especially common in lesions larger than
1.5 cm in size, whereas smaller lesions sometimes demon-
strate homogeneous enhancement. In these cases, splenic
vein involvement may be observed. In portal and delayed
phase images, the lesions demonstrate a rapid wash-out
between 60 and 120 s [8, 9, 15].
It should be emphasised that metastases from many pri-
mary hypovascular tumours (lung, colonic, gastric cancers)
often present as hypoattenuated lesions compared to the
normal enhanced pancreas after i.v. injection, while metas-
tases from primary hypervascular tumours (HCC, thyroid,
renal cell cancers) also display increased vascularity on
contrast-enhanced CT.
On MR imaging, pancreatic lesions typically appear
hypointense compared with normal gland tissue on unen-
hanced T1-weighted images, both with and without fat
saturation. On T2-weighted images, the lesions have hetero-
geneous or moderately hyperintense signal [14]. Hypoin-
tense nodules are sometimes visible on T2-weighted images,
Fig. 4 Two metastatic lesions are depicted on contrast-enhanced CT in
the pancreatic tail (arrow in a) and head (arrow in b), in a 70-year-old
male patient suffering from lung cancer, 1 year after chemotherapy.
Right adrenal metastasis (arrowhead in a) as well as a peripancreatic
lymph node (arrowhead in b) are also demonstrated
Fig. 5 A 35-year-old woman who underwent liver surgery due to
hepatocellular carcinoma. Two years later, the follow-up CT scan
revealed intrahepatic biliary dilatation and slight pancreatic duct dila-
tation (a) due to metastatic infiltration of the pancreatic head (arrow in
b) proven by EUS-FNA
Fig. 6 A 55-year-old man, 8 months after left hemicolectomy due to a
low-differentiated cancer. Tumour recurrence is evident (arrow in a),
as well as an extensive pancreatic body and tail diffuse infiltration
(arrowheads in a and b)
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netic contrast administration, a rim of enhancement is usu-
ally visible in larger lesions and homogeneous enhancement
is typically demonstrated in smaller tumours, as seen on CT
scans.
The transition from uniform enhancement in small me-
tastases to ring enhancement in larger metastases relates to
the blood supply to these tumours. The metastases parasitize
blood supply from the surrounding organ, which will result
in a uniform tumour blush in small lesions [21, 22]. In larger
lesions, the peripheral aspect of the tumour receives a better
blood supply than the more hypovascular central portion,
which results in a predominant ring enhancement pattern on
early postcontrast images.
Dilatation of the main pancreatic duct is not a common
finding, but when present, differential diagnosis from pri-
mary pancreatic cancer is extremely difficult (Fig. 9). An
observation we have made, not previously reported, is the
presence of the “duct penetrating sign,” a feature that has
been so far related only to focal pancreatitis (Fig. 10). The
explanation could be that primary pancreatic cancer in fact
represents an adenocarcinoma of the duct itself, while meta-
static lesions arise outside the ducts and may only affect
them secondarily by compression or rarely infiltration.
It should be noted that an appropriate imaging protocol is
essential for the diagnosis of pancreatic metastases. This is
of particular importance for metastases from renal cell car-
cinomas that demonstrate intense early enhancement both at
CT and MRI, a pattern that reflects hypervascularity of
viable tumour tissue and is the main differential diagnostic
feature from the hypovascular pancreatic adenocarcinoma
(Fig. 9)[ 8, 9, 14]. Such metastases may fail to be appreci-
ated in the delayed phase. Therefore in patients with sus-
pected renal cell carcinoma metastases to the pancreas,
early-phase scanning after i.v. contrast administration
should be performed [23].
Although the solitary type is the most common in pan-
creatic metastases from renal cell carcinoma, multifocality
of the lesions is not unusual, ranging from 20 to 45% in
different reports (Fig. 11)[ 24–28]. Multifocal lesions may
also be found in cases of lung cancer or colonic cancer
Fig. 7 EUS image showing a large metastatic lesion from renal cell
cancer confirmed by FNA, cytology, and immunohistochemical anal-
ysis, in a 56-year-old male presenting with jaundice
Fig. 8 EUS image revealing a hypoechoic metastatic lesion from non-
small-cell lung cancer confirmed by FNA, cytology, and immunohis-
tochemical analysis, in a 66-year-old male presenting with abdominal
pain
Fig. 9 A 63-year-old woman who underwent left nephrectomy due to
renal cell carcinoma. Three years later, the follow-up CTscan revealed
a metastatic lesion with intense contrast enhancement in the uncinate
process of the pancreas (arrow in a), causing dilatation of the main
pancreatic duct in the body and tail that was evaluated by MRCP (b)
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imaging features, but in some cases where small and larger
metastases co-exist, some differences may be noticed in all
imaging modalities and differential diagnostic problems
may arise.
Differential diagnosis and pitfalls
In most cases the diagnosis of secondary pancreatic
tumours, along with the differential diagnosis of primary
pancreatic adenocarcinomas, can still be difficult, due to a
multiplicity of factors. Firstly, CT can occasionally fail to
show subtle differences in attenuation between normal pan-
creatic tissue and nonnecrotic or noncystic neoplastic tissue;
this issue becomes especially crucial when confronting
small metastatic nodules which do not alter the normal
contour of the pancreas, and this deception can only occa-
sionally be prevented by dynamic CT [12].
In addition, one of the patterns of pancreatic involvement
is a diffuse homogeneous infiltration of the organ, which
then appears simply enlarged, but without any sign of focal
disease, a deceiving appearance both at US and CT [11, 12].
This appearance, quite similar to a diffuse lymphomatous
infiltration, may present serious difficulties in the differential
diagnosis, especially if accompanied by a visible involvement
of the locoregional lymph nodes.
Also, nonhyperfunctioning islet cell carcinoma can be
indistinguishable from some metastatic cancers to the pan-
creas that do not closely resemble the common ductal type
Fig. 10 A 70-year-old man who underwent surgery for lung cancer.
Six months later, he developed a solitary metastatic lesion in the
pancreatic body evaluated by CT (arrow in a) and MRI (b). Note that
the pancreatic duct “penetrates” the metastatic lesion with no evidence
of infiltration on the T2-weighted image (arrow in b)
Fig. 11 A 48-year-old man with
a history of right nephrectomy
due to renal cell cancer. Two
years after, he developed two
metastatic lesions in the pancre-
atic body and head that were
hyperdense after contrast en-
hancement (arrows in a and b).
He received targeted chemother-
apy and the follow-up CT scan
revealed a very good response
proven by the reduced vascularity
(arrows in c and d)
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renal cell carcinoma shares morphologic and imaging fea-
tures with nonhyperfunctioning islet cell carcinoma. Both
types of tumour are typically hypervascular but are subject
to central necrosis and cystic degeneration [29–32]. Although
the imaging features of the metastatic lesions along with
a history of prior nephrectomy for renal cell carcinoma aid
in postulating the diagnosis, histological verification is
mandatory.
Finally, hemorrhagic-necrotising pancreatitis can imitate
the appearance of multiple pancreatic metastases, as it
presents preserved organ parenchyma and necrotic hypoe-
choic areas side by side. Because pancreatic metastases can
also give rise to severe pancreatitis with development of
necrotic tracts [33], differential diagnosis is extremely diffi-
cult in these cases.
However, CEUS, CT, and MRI may demonstrate features
that aid in distinguishing metastatic from primary cancer of
the pancreas. For example, the enhancement of tumour
tissue reflects a degree of vascular perfusion that is not
typical of primary pancreatic adenocarcinoma. Whereas
ductal adenocarcinoma of the pancreas typically appears as
a uniformly nonenhancing mass at contrast-enhanced CT
[34], a large proportion of pancreatic metastases enhance
perceptibly, either heterogeneously or, less commonly, ho-
mogeneously. Metastases from renal cell carcinomas are
often seen as hyperattenuating masses, often with nonen-
hancing internal components. This pattern, which reflects
hypervascularity of viable tumour tissue and diminished or
absent perfusion of necrotic components, is also typical of
primary renal cell carcinomas [29].
Metastatic pancreatic tumours may also have certain im-
aging features that are more characteristic of their extrap-
ancreatic sources than of primary pancreatic cancer.
Multiplicity of tumours within the pancreas, although rela-
tively common in metastasis to the pancreas, is not charac-
teristic of primary pancreatic carcinoma. Coexisting
metastases at sites that are not typically involved with ade-
nocarcinoma of pancreatic origin, such as the skeleton or
adrenal glands, should also suggest the possibility of meta-
static disease of the pancreas. Metastasis may also be more
likely when there is a large tumour of the pancreatic head
without a dilated bile duct and when the retropancreatic fat
is not obliterated in a patient with a large pancreatic mass
[15].
Intratumoural calcification is not characteristic of prima-
ry ductal adenocarcinoma of the pancreas, although it has
been reported as a rare occurrence in that relatively common
tumour [30]. Calcification occurs more frequently in some
of the less common types of primary pancreatic neoplasia
such as islet cell carcinoma [31, 32].
Focal infiltration of the pancreas in Hodgkin and non-
Hodgkin lymphomas has been described in the US literature
thus far exclusively as large, solitary, hypoechoic, space-
occupying lesions [35, 36] .T h ep r e s e n c eo fp a r a - a o r t i c
lymph nodes and the fact that the underlying disease usually
is already known at the time pancreatic lesions are demon-
strated facilitate differential diagnosis.
Treatment
Pancreatic metastases are rare and the possible benefit of sur-
gical treatment is not clearly defined. However, surgical resec-
tion can be performed safely in patients with isolated pancreatic
metastases from colorectal cancer and in selected patients with
associated extrapancreatic disease. Although long-term surviv-
al is rare, surgery should be included, whenever possible, in the
multimodality approach to this disease [37].
In patients with pancreatic metastases from renal cell
cancer (RCC) who have only limited disease, complete
resection of all lesions can be successfully performed with
a low rate of complications [38]. It seems that lesion size
and the number of metastases may predict survival after
resection, but sufficient data are not available. In a retro-
spective study involving 220 patients, it was shown that
survival after resection of RCC with isolated metastasis to
the pancreas is favorable [39]. However, a more detailed
analysis considering outcomes without surgery for each
primary tumour site is needed before the value of this
aggressive surgical approach can be completely assessed
in the general occurrence of pancreatic metastasis.
Sunitinib recently showed clinical efficacy in patients
with advanced renal cell carcinoma. According to the results
of a recent study [40] it seems that sunitinib could be also
effective in patients with pancreatic metastasis (Fig. 11).
This raises the question of whether patients with metastatic
renal cell carcinoma limited to the pancreas may derive
greater clinical benefit from anti-angiogenic agents, rather
than from aggressive surgical resection. However, surgery
remains the only potential cure in patients with isolated
pancreatic metastasis.
Conclusion
Pretherapeutic diagnosis of a secondary pancreatic tumour is
essential for proper patient management. In certain cases
prolonged survival may be achieved with successful surgi-
cal resection. Radiologists should be familiar with the dif-
ferent imaging appearances of pancreatic metastases and be
aware that they may encounter this diagnosis not only in
cases of multiple pancreatic lesions but also when a single
atypical lesion is found even incidentally. In patients with a
history of a malignant tumour, a newly diagnosed mass in
the pancreas should raise the suspicion of metastatic disease.
Insights Imaging (2012) 3:165–172 171In doubtful cases the absence of vessel infiltration and/or the
normal pancreatic duct appearance favors the diagnosis of
pancreatic metastasis.
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